Cytokinetics, Incorporated

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). It also develops Aficamten, a cardiac myosin inhibitor for hypertrophic cardiomyopathy (HCM), and omecamtiv mecarbil, a potential treatment for heart failure with severely reduced ejection fraction. Additionally, Cytokinetics is developing Ulacamten, a cardiac myosin inhibitor for heart failure with preserved ejection fraction, and CK-089, a fast skeletal muscle troponin activator, both in Phase 1 clinical trials.

Cytokinetics is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol CYTK. The company's stock trades in US Dollars (USD), reflecting its primary listing in the United States. As a US-based biopharmaceutical company, its financial reporting and market transactions are conducted in USD, which is the standard currency for Nasdaq-listed companies.

Cytokinetics operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies like Cytokinetics focus on using biological processes to develop therapies for medical conditions. In Cytokinetics' case, it specializes in muscle biology, developing small molecule drugs that target cardiac and skeletal muscle function to treat debilitating diseases such as hypertrophic cardiomyopathy and heart failure.

Cytokinetics is headquartered in South San Francisco, California, United States. The company primarily serves the US market, as indicated by its focus on the United States in its description. Its commercial product MYQORZO and pipeline candidates are developed for the US healthcare system, targeting conditions like hypertrophic cardiomyopathy and heart failure. The company was incorporated in 1997 and has since concentrated its research, development, and commercialization efforts within the US.

Cytokinetics' main commercial product is MYQORZO, a novel oral small molecule cardiac myosin inhibitor approved for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Its pipeline includes Aficamten, another cardiac myosin inhibitor for hypertrophic cardiomyopathy (HCM), and omecamtiv mecarbil, a potential treatment for heart failure with severely reduced ejection fraction. Earlier-stage candidates are Ulacamten, a cardiac myosin inhibitor for heart failure with preserved ejection fraction, and CK-089, a fast skeletal muscle troponin activator, both in Phase 1 trials. These products and candidates reflect the company's focus on muscle biology to address cardiovascular and muscle-related diseases.